Overview

LCS12 vs. ENG Subdermal Implant (Nexplanon) Discontinuation Rate Study

Status:
Completed
Trial end date:
2015-04-01
Target enrollment:
Participant gender:
Summary
The primary objective is to demonstrate that discontinuation rates in women (ages 18-35 years inclusive) using LCS12 are not higher than those seen in women using ENG subdermal implant over a period of 12 months. Secondary objectives are to observe the bleeding patterns, adverse event profiles and the occurrence of unintended pregnancies. Additionally, data on user satisfaction, IUS expulsions and implant site complications will be collected.
Phase:
Phase 3
Details
Lead Sponsor:
Bayer
Treatments:
Etonogestrel